Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Despite high organ toxicity, CD19 CART T cell therapy shows low nonrelapse mortality

Key clinical point: The 1-year nonrelapse mortality and overall survival were 1.7% and 69%, respectively.

Major finding: A total of 539 grade 2 or greater and 280 grade 3 or greater toxicities were observed.

Study details: Toxicities in organ-based groups assessed in 60 patients with DLBCL treated with CD19 CAR T cells.

Disclosures: The authors reported various relationships with multiple pharmaceutical and biotechnology companies.


Wudhikarn K et al. Blood Advances. 2020; 4[13]:3024-33.